Benzinga | Jul 20, 2021 06:09AM EDT

HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Raises Price Target to $19

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy and raises the price target from $11 to $19.